ClinicalTrials.gg
TerminatedNCT00642902ATAMSUpdated May 24, 2016Results posted

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)

A Phase 2 interventional study of Atacicept and Atacicept in Relapsing Multiple Sclerosis, sponsored by EMD Serono. Terminated at 51 sites in 17 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2016-05-24.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor voluntarily decided to terminate trial due to increased MS disease activity in atacicept arms as compared to placebo during a routine IDMC review.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany — none open to participants now, 1 under way, none of them phase 3. Multiple Sclerosis · Merck KGaA, Darmstadt, Germany.

Enrollment
14th of 33
255 · median 219
Started
2008
with 12 others
Phase 2
9 of 71
none open now
Registered
8th of 71
by date

Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, this one is the 14th largest by enrollment of the 33 interventional ones that give a count, is one of 13 that started in 2008, is one of 9 in phase 2, and was the 8th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 664 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany is open now. The open studies under Multiple Sclerosis, anywhere →

Who these studies take

Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany as a file.
02

Study summary

To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces central nervous system inflammation in subjects with relapsing multiple sclerosis (RMS) as assessed by frequent magnetic resonance imaging (MRI). This study is randomised. Study medication is administered via subcutaneous (under the skin) injections.

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

Keywords

  • Relapsing Multiple Sclerosis
  • Atacicept
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RMS (as per McDonald criteria, 2005) Other protocol-defined inclusion criteria could apply.

Exclusion criteria

Exclusion Criteria:

  • Have primary progressive multiple sclerosis (MS)
  • Have secondary progressive MS without superimposed relapses
  • Relevant cardiac, hepatic and renal diseases as specified in the protocol
  • Pretreatment with and immunomodulating drugs as specified in the protocol
  • Clinical significant abnormalities in blood cell counts and immunoglobulin levels as specified in the protocol
  • Clinical significant acute or chronic infections as specified in the protocol Other protocol-defined exclusion criteria could apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    Atacicept 25 mg

    Drug: Atacicept

  • Experimental
    Atacicept 75 mg

    Drug: Atacicept

  • Experimental
    Atacicept 150 mg

    Drug: Atacicept

  • Placebo comparator
    Placebo

    Drug: Placebo matched to atacicept

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Participant Per Scan

    Analysis of T1 Gd-enhancing lesions was done using magnetic resonance imaging (MRI) scans. Only post-baseline scans were included in the calculation of this endpoint (excluding the Study Day 1 scan which had been conducted before first dosing).

    Time frame: Weeks 12 to 36

Secondary outcomes

  1. Number of New T1 Gd-enhancing Lesions Per Participant

    Analysis of new T1 Gd-enhancing lesions was done using MRI scans.

    Time frame: Weeks 12, 24, 36

  2. Percentage of Participants Free From Relapses

    A relapse was defined as the fulfillment of all the following criteria: a) neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both i) neurological abnormality separated by at least 30 days from onset of a preceding clinical event, and ii) neurological abnormality lasting for at least 24 hours; b) absence of fever or known infection (fever with temperature \[axillary, orally, or intrauriculary\] greater than (\>) 37.5 degrees Celsius or 99.5 degrees Fahrenheit); and c) objective neurological impairment, correlating with the participant's reported symptoms, defined as either i) increase in at least 1 of the functional systems of the Expanded Disability Status Scale (EDSS), or ii) increase of the total EDSS score. Percentage of participants free from relapses during 36-week treatment period was reported.

    Time frame: Baseline up to Week 36

  3. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-emergent are events between first dose of study drug up to 12 weeks after the last dose of the study drug that were absent before treatment or that worsened relative to pretreatment state. Number of subjects with TEAEs included subjects with both non serious and serious TEAEs.

    Time frame: From the first dose of study drug administration up to 12 weeks after the last dose of the study drug

07

Results

Posted May 24, 2016
Limitations and caveats
Sponsor voluntarily decided to prematurely terminate this trial due to an increase in multiple sclerosis (MS) disease activity observed in atacicept arms as compared to placebo during a routine independent data monitoring committee (IDMC) review.

Participant flow

Participant flow — Overall Study
MilestonePlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
Started63636465
Treated63636365
Completed23212125
Not completed40424340
Withdrew: Adverse event0131
Withdrew: Lost to follow-up1100
Withdrew: Lack of efficacy0330
Withdrew: Death1000
Withdrew: Premature termination of clinical trial37323535
Withdrew: Randomized, but not treated0010
Withdrew: Other1514

Outcome measures

PrimaryMean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Participant Per Scan

Analysis of T1 Gd-enhancing lesions was done using magnetic resonance imaging (MRI) scans. Only post-baseline scans were included in the calculation of this endpoint (excluding the Study Day 1 scan which had been conducted before first dosing).

Time frame:
Weeks 12 to 36
Reported as:
Mean · lesions/participant/scan
Mean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Participant Per Scan
lesions/participant/scanPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
Mean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Participant Per Scan3.07 (1.40 to 6.77)2.26 (0.97 to 5.27)2.30 (1.08 to 4.92)2.49 (1.18 to 5.27)
SecondaryNumber of New T1 Gd-enhancing Lesions Per Participant

Analysis of new T1 Gd-enhancing lesions was done using MRI scans.

Time frame:
Weeks 12, 24, 36
Reported as:
Mean · lesions/participant
Number of New T1 Gd-enhancing Lesions Per Participant
lesions/participantPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
Week 12 (n=55, 45, 50, 55)2.55 ± 7.952.71 ± 7.673.20 ± 6.412.96 ± 6.58
Week 24 (n=41, 34, 37, 41)0.83 ± 1.701.50 ± 2.791.54 ± 2.961.54 ± 2.94
Week 36 (n=23, 22, 24, 26)0.43 ± 0.901.68 ± 5.091.38 ± 1.930.54 ± 1.07
SecondaryPercentage of Participants Free From Relapses

A relapse was defined as the fulfillment of all the following criteria: a) neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both i) neurological abnormality separated by at least 30 days from onset of a preceding clinical event, and ii) neurological abnormality lasting for at least 24 hours; b) absence of fever or known infection (fever with temperature \[axillary, orally, or intrauriculary\] greater than (\>) 37.5 degrees Celsius or 99.5 degrees Fahrenheit); and c) objective neurological impairment, correlating with the participant's reported symptoms, defined as either i) increase in at least 1 of the functional systems of the Expanded Disability Status Scale (EDSS), or ii) increase of the total EDSS score. Percentage of participants free from relapses during 36-week treatment period was reported.

Time frame:
Baseline up to Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Free From Relapses
percentage of participantsPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
Percentage of Participants Free From Relapses81.069.871.961.5
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-emergent are events between first dose of study drug up to 12 weeks after the last dose of the study drug that were absent before treatment or that worsened relative to pretreatment state. Number of subjects with TEAEs included subjects with both non serious and serious TEAEs.

Time frame:
From the first dose of study drug administration up to 12 weeks after the last dose of the study drug
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
participantsPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
TEAEs46403952
Serious TEAEs1331

Adverse events

Collected over From the first dose of study drug administration up to 12 weeks after the last dose of the study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/63 (1.6%)33/63 (52.4%)
Atacicept 25 mg—3/63 (4.8%)30/63 (47.6%)
Atacicept 75 mg—3/63 (4.8%)34/63 (54%)
Atacicept 150 mg—1/65 (1.5%)44/65 (67.7%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
PneumothoraxRespiratory, thoracic and mediastinal disorders0/630/632/630/65
Myocardial infarctionCardiac disorders1/630/630/630/65
Hip fractureInjury, poisoning and procedural complications0/631/630/630/65
Humerus fractureInjury, poisoning and procedural complications0/631/630/630/65
Acute psychosisPsychiatric disorders0/631/630/630/65
PleurisyRespiratory, thoracic and mediastinal disorders0/630/631/630/65
Bronchopleural fistulaRespiratory, thoracic and mediastinal disorders0/630/631/630/65
Lung abscessInfections and infestations0/630/631/630/65
PyothoraxInfections and infestations0/630/631/630/65
PneumoniaInfections and infestations0/630/631/630/65
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
Injection site reactionGeneral disorders8/6319/6324/6332/65
NasopharyngitisInfections and infestations6/634/637/6313/65
HeadacheNervous system disorders11/638/633/636/65
Upper respiratory tract infectionInfections and infestations3/631/634/638/65
Urinary tract infectionInfections and infestations3/634/637/633/65
InfluenzaInfections and infestations5/631/631/632/65
BronchitisInfections and infestations1/632/631/635/65
DiarrhoeaGastrointestinal disorders1/631/633/635/65
Back painMusculoskeletal and connective tissue disorders4/630/633/633/65
Pain in extremityMusculoskeletal and connective tissue disorders4/633/631/631/65

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mgTotal
Mean37.7 ± 10.537.5 ± 8.538.0 ± 10.137.5 ± 10.537.7 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mgTotal
Female45344446169
Male1829201986
08

Study locations

51 sites
  • Research Site
    Phoenix, Arizona, United States
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    Northbrook, Illinois, United States
  • Research Site
    East Lansing, Michigan, United States
  • Research Site
    Dartmouth, New Hampshire, United States
  • Research Site
    Cleveland, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Research Site
    Nashville, Tennessee, United States
  • Research Site
    Box Hill, Australia
  • Research Site
    Fitzroy, Australia
  • Research Site
    New Lambton, Australia
  • Research Site
    Woodville, Australia
  • Research Site
    Innsbruck, Austria
  • Research Site
    Diepenbeek, Belgium
  • Research Site
    Sijsele, Belgium
  • Research Site
    Calgary, Alberta, Canada
  • Research Site
    Ottawa, Ontario, Canada
  • Research Site
    Ontario, Canada
  • Research Site
    Brno, Czech Republic
  • Research Site
    Hradec Kralove, Czech Republic
  • Research Site
    Olomouc, Czech Republic
  • Research Site
    Caen, France
  • Research Site
    Saint-Herblain, France
  • Research Site
    Bochum, Germany
  • Research Site
    Dusseldorf, Germany
  • Research Site
    Beirut, Lebanon
  • Research Site
    Beyrouth, Lebanon
  • Research Site
    Kaunas, Lithuania
  • Research Site
    Breda, Netherlands
  • Research Site
    Nieuwegein, Netherlands
  • Research Site
    Rotterdam, Netherlands
  • Research Site
    Dnipropetrovsk, Russian Federation
  • Research Site
    Ekaterinburg, Russian Federation
  • Research Site
    Moscow, Russian Federation
  • Research Site
    Novosibirsk, Russian Federation
  • Research Site
    Saint Petersburg, Russian Federation
  • Research Site
    Samara, Russian Federation
  • Research Site
    Vladimir, Russian Federation
  • Research Site
    Yaroslavl, Russian Federation
  • Research Site
    Barcelona, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Malaga, Spain
  • Research Site
    Stockholm, Sweden
  • Research Site
    Basel, Switzerland
  • Research Site
    Kharkiv, Ukraine
  • Research Site
    Kyiv, Ukraine
  • Research Site
    Odessa, Ukraine
  • Research Site
    Uzhgorod, Ukraine
  • Research Site
    London, United Kingdom
  • Research Site
    Sheffield, United Kingdom
  • Research Site
    Stoke on Trent, United Kingdom
09

References and documents

Publications

  • Kappos L, Hartung HP, Freedman MS, Boyko A, Radu EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J; ATAMS Study Group. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 2014 Apr;13(4):353-63. doi: 10.1016/S1474-4422(14)70028-6. Epub 2014 Mar 6. PubMed 24613349 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 6 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2008
First posted
Mar 25, 2008
Start
Apr 2008
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
May 24, 2016
Last update
May 24, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00642902
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Mar 25, 2008
Start date
Apr 2008
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
May 24, 2016
Last update
May 24, 2016

Study contacts

Medical Responsible
study director · EMD Serono, an affiliate of Merck KGaA Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein

Start the discussion